CIK 0001534120 · Non-accelerated filer<br>Smaller reporting company
Avalo Therapeutics, Inc.
Sign in to watch- Ticker
- AVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 450705648
- Phone
- 410-522-8707
- Business address
- 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE, PA, 19087
- Former names
- Cerecor Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,865,893
- in 5 filings, $1.9M under 10b5-1 plans
Net −$1,865,893. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-16 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise 10b5-1 | +12,394 | $9.88 | $122K | 52,294 |
| 2026-09-16 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −12,394 | $16.33 | $202K | 39,900 |
| 2026-09-16 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,394 | 83,848 | ||
| 2026-09-10 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise 10b5-1 | +10,185 | $8.04 | $82K | 50,085 |
| 2026-09-10 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −10,185 | $17.62 | $179K | 39,900 |
| 2026-09-10 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,185 | 105,815 | ||
| 2026-08-18 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise 10b5-1 | +31,031 | $9.88 | $307K | 70,931 |
| 2026-08-18 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −31,031 | $20.05 | $622K | 39,900 |
| 2026-08-18 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −31,031 | 96,242 | ||
| 2026-08-17 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise 10b5-1 | +37,945 | $9.88 | $375K | 78,718 |
| 2026-08-17 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise 10b5-1 | +2,876 | $9.88 | $28K | 81,594 |
| 2026-08-17 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −37,945 | $19.85 | $753K | 43,649 |
| 2026-08-17 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −3,749 | $19.94 | $75K | 39,900 |
| 2026-08-17 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −37,945 | 130,149 | ||
| 2026-08-17 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,876 | 127,273 | ||
| 2026-06-10 | Sullivan Christopher Ryan Chief Financial Officer | Shares withheld for taxes | −138 | $13.10 | $2K | 40,773 |
| 2026-05-21 | Sullivan Christopher Ryan Chief Financial Officer | Grant or award | +39,900 | 40,323 | ||
| 2026-05-07 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise 10b5-1 | +18,606 | $9.88 | $184K | 19,029 |
| 2026-05-07 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −18,606 | $24.12 | $449K | 423 |
| 2026-05-07 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −18,606 | 168,094 |
Page 1 of 3 · 44 trades